BTG3 and Miscarriage: The miscarriage rate was lower than that of the control group, and the differences were statistically significant, suggesting that drug treatment can improve the pregnancy outcomes of patients with ANA‐positive immune‐related RSA, increasing the live birth rate after re‐pregnancy, and reducing the miscarriage rate after re‐pregnancy.